ESTIMATED
05/10/2024
05/10/2024
(AS OF MARCH 31)
Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
---|---|---|---|---|
Q1 2024 | 0 | -$0.02 | -$0.02 | -$0.02 |
Q2 2024 | 1 | $0.02 | $0.02 | $0.02 |
Q3 2024 | 0 | $0.06 | $0.06 | $0.06 |
Q4 2024 | 0 | $0.10 | $0.10 | $0.10 |
Protalix BioTherapeutics, Inc. last posted its earnings results on Friday, May 10th, 2024. The company reported $-0.06 earnings per share for the quarter, missing analysts' consensus estimates of $-0.02 by $0.04. The company had revenue of 3.75 M for the quarter and had revenue of 65.49 M for the year. Protalix BioTherapeutics, Inc. has generated $0 earnings per share over the last year ($0.0867 diluted earnings per share) and currently has a price-to-earnings ratio of 11.2. Protalix BioTherapeutics, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, August 5th, 2024 based on prior year's report dates.
Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue | 05/10/2024 | Q1 2024 | -$0.02 | -$0.06 | -0.04 | $9.20 M | $3.75 M | 03/14/2024 | Q4 2023 | -$0.03 | -$0.08 | -0.05 | $8.15 M | $10.49 M | 11/06/2023 | Q3 2023 | -$0.07 | -$0.03 | 0.04 | $10.35 M | 08/07/2023 | Q2 2023 | $0.03 | $0.29 | 0.26 | $35.08 M | 05/04/2023 | Q1 2023 | -$0.05 | $9.57 M | $9.59 M | 02/27/2023 | Q4 2022 | -$0.15 | -$0.07 | 0.08 | $6.12 M | $8.62 M | 11/14/2022 | Q3 2022 | -$0.15 | -$0.08 | 0.07 | $14.18 M | 08/15/2022 | Q2 2022 | -$0.18 | -$0.11 | 0.07 | $8.75 M | 05/16/2022 | Q1 2022 | -$0.06 | $16.09 M | 03/31/2022 | Q4 2021 | -$0.11 | -$0.15 | -0.04 | $7.79 M | $8.55 M | 11/15/2021 | Q3 2021 | -$0.12 | -$0.09 | 0.03 | $6.90 M | $12.05 M | 08/16/2021 | Q2 2021 | -$0.08 | -$0.25 | -0.17 | $8.30 M | $6.43 M | 05/14/2021 | Q1 2021 | -$0.17 | -$0.14 | 0.03 | $11.32 M | 03/30/2021 | Q4 2020 | -$0.09 | $0.01 | 0.1 | $11.98 M | $19.50 M | 10/29/2020 | Q3 2020 | -$0.08 | -$0.14 | -0.06 | $13.56 M | $10.79 M | 08/10/2020 | Q2 2020 | -$0.21 | -$0.13 | 0.08 | $10.87 M | $10.97 M | 06/01/2020 | Q1 2020 | -$0.30 | $0.10 | 0.4 | $21.65 M | 03/12/2020 | Q4 2019 | -$0.25 | $0.02 | 0.27 | $10.20 M | $17.76 M | 11/07/2019 | Q3 2019 | -$0.40 | -$0.24 | 0.16 | $11.60 M | $14.25 M | 08/08/2019 | Q2 2019 | -$0.30 | -$0.52 | -0.22 | $11.75 M | $12.25 M |
---|
A. Protalix BioTherapeutics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, August 5th, 2024 based off last year's report dates.
A. The conference call for Protalix BioTherapeutics, Inc.'s latest earnings report can be listened to online.
A. The conference call transcript for Protalix BioTherapeutics, Inc.'s latest earnings report can be read online.
A. Protalix BioTherapeutics, Inc. (AMEX:PLX) has a recorded annual revenue of $65.49 M.
A. Protalix BioTherapeutics, Inc. (AMEX:PLX) has a recorded net income of $65.49 M. Protalix BioTherapeutics, Inc. has generated $0.12 earnings per share over the last four quarters.
A. Protalix BioTherapeutics, Inc. (AMEX:PLX) has a price-to-earnings ratio of 11.2 and price/earnings-to-growth ratio is 1.19.